A target is conventionally considered to be validated when there is evidence that modulation of a target molecule will produce a desired biological effect. Integrative Proteomics Inc. is taking that definition one step further. It hopes to churn out higher quality targets by defining a validated target as one that not only plays a role in a biological pathway, but also is one that is druggable, with a structural cleft with which a drug can interact.

"The key is the intersection of druggable targets and chemistry," according to John Mendlein, chairman and CEO. "There are a lot of targets out there, but many of them are intractable."